Genmab — November 2016
-
Men
-
Men i og med at Darzalex er firstmover, så riskierer Isatuximab vel en skæbne som Arzerra har p.t.?
-
Ja måske, men det var vel ikke det de oprindeligt regnede med. Men de kan selvfølgelig være tilfreds med mindre nu, og håbe på at komme ind i senere linier når patienterne er blevet dara resistente
-
Amgen, Janssen Show Commitment to Multiple Myeloma Research - See more at: http://www.ajpb.com/articles/amgen-janssen-show-commitment-to-multiple-myeloma-research#sthash.8bdYSgPS.dpuf
-
Ikke helt nyt. Det var den pressemeddelelse Genmab udsendte i torsdags. Men dara er sammen med Kyprolis med helt fremme i ASCENT-studiet i high risk smoldering myeloma, som starter formentlig i år. http://www.myelomacrowd.org/the-rosseta-stone-for-a-myeloma-cure-early-treatment-of-high-risk-smoldering-myeloma/ og http://www.curetalks.com/event/rsvp/Understanding-ASCENT-Clinical-Trial-for-High-Risk-Smoldering-Myeloma-Patients-/255/
-
http://www.myelomabeacon.com/pr/2016/09/27/clarion-trial-kyprolis-velcade-melphalan-prednisone/ Kyprolis missede for nylig first line i head to head imod Velcade - big faliure for Amgen og deres $10 bn investering.
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind